Tech Company Financing Transactions
KinDex Pharmaceuticals Funding Round
On 3/26/2014, KinDex Pharmaceuticals raised $5 million in Series A funding from Polaris Partners.
Transaction Overview
Company Name
Announced On
3/26/2014
Transaction Type
Venture Equity
Amount
$5,000,000
Round
Series A
Investors
Proceeds Purpose
Their investment will help us initiate the planned Phase 2 trial of our most advanced candidate, KDT501, in Type 2 diabetic patients as well as undertake additional preclinical and mechanistic studies in brown fat biology.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
265 Franklin St. 1702
Boston, MA 02110
USA
Boston, MA 02110
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
KinDex was established in the fall of 2009 to focus on the discovery and development of molecules that modulate key regulatory networks associated with chronic disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Michael Higgins
VP - Bus. Development
Paul Rogers
Browse more venture capital transactions:
Prev: 3/26/2014: Axonics Modulation Technologies venture capital transaction
Next: 3/26/2014: ConnectAndSell venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. All VC database entries on this site are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs